Solenic Medical Announces Breakthrough in Treating Implant Infections

New research shows alternating magnetic fields enhance antibiotic effectiveness against biofilms across multiple pathogens and materials.

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Solenic Medical has published peer-reviewed research in Scientific Reports demonstrating that alternating magnetic fields (AMF) significantly enhance antibiotic activity against bacterial biofilms across a broad range of pathogens and antibiotics. This addresses a central challenge in the treatment of metallic implant-associated infections, as biofilm formation on implanted medical devices is a major contributor to chronic and recurrent infections.

Why it matters

Biofilm-associated infections remain one of the most difficult challenges in orthopedic care, often requiring complex surgical revision and prolonged antibiotic therapy. The findings support the potential of Solenic's AMF platform to improve the efficacy of existing antimicrobial therapies without additional surgery, addressing a critical unmet need in implant-associated infection treatment.

The details

The research evaluated the impact of AMF in combination with antibiotics on biofilm-associated bacteria relevant to prosthetic joint infections (PJIs). The results show that AMF exposure combined with antibiotics markedly reduced biofilm compared to antibiotics alone, including against both Gram-positive and Gram-negative organisms. Importantly, the enhanced anti-biofilm effect was observed across different antibiotics and bacterial species, and was not dependent on the specific metal composition of the implant surface, suggesting broad applicability.

  • The peer-reviewed research was published in Scientific Reports on February 26, 2026.

The players

Solenic Medical, Inc.

A medical device company founded to develop and commercialize a method for treating implant infections, with an initial focus on prosthetic joint infections (PJI).

Bart Bandy

The CEO of Solenic Medical.

Dr. David Greenberg

The Chief Medical Officer and co-founder of Solenic Medical, and a co-author of the Scientific Reports findings and co-inventor of the AMF technology.

Got photos? Submit your photos here. ›

What they’re saying

“This publication provides strong peer-reviewed validation of our AMF platform and its ability to enhance antibiotic activity against biofilms.”

— Bart Bandy, CEO, Solenic Medical

“Seeing this consistent enhancement across multiple pathogens, antibiotics, and implant materials reinforces the potential of alternating magnetic fields as a broadly applicable adjunct to antimicrobial therapy.”

— Dr. David Greenberg, Chief Medical Officer and co-founder, Solenic Medical

What’s next

Solenic Medical is advancing its AMF technology toward clinical translation for the treatment of prosthetic joint infections and other implant-related infections.

The takeaway

Solenic's non-invasive AMF platform has the potential to significantly improve outcomes in implant-associated infections by enhancing the effectiveness of existing antimicrobial therapies, addressing a critical unmet need in orthopedic care.